SOST and Arthritis: Blocking sclerostin by a monoclonal antibody in human tumor necrosis factor transgenic (hTNFtg) mice model of arthritis reduces loss of systemic bone mass, periarticular bone destruction and cartilage damage, without any effect on inflammation.